Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25982824 | 1.00 | GNAI3 (0.33) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL25982823 | 1.00 | GNAI3 (0.33) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL16111358 | 0.83 | GNAI3 (0.39) | GNAI3GNAO1GNAI1 | |
| SCHEMBL27416382 | 0.80 | GNAI3 (0.44) | GNAI3GNAO1GNAI1 | |
| SCHEMBL24549375 | 0.78 | GNAI3 (0.33) | GNAI3GNAO1GNAI1 | |
| SCHEMBL14767903 | 0.77 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL25530401 | 0.77 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL4168941 | 0.77 | GNAI3 (0.32) | GNAI3GNAO1GNAI1 | |
| SCHEMBL12942170 | 0.76 | — | — | |
| SCHEMBL10196493 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2022261210-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2007000771-A2 | FUSED QUINAZOLINONE DERIVATIVES AND USES THEREOF | RIMONYX PHARMACEUTICALS LTD. (IL) | 2007-01-04 | — | — | WO | disclosed |
| CN-1204121-C | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2005-06-01 | — | — | CN | disclosed |
| CN-1253547-A | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | GNAI3 952/4885GNAO1 1069/4885GNAI1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.